DNA	O
damage	O
induces	O
a	O
novel	O
p53	O
-	O
survivin	O
signaling	O
pathway	O
regulating	O
cell	B-Cell
cycle	O
and	O
apoptosis	O
in	O
acute	B-Cell
lymphoblastic	I-Cell
leukemia	I-Cell
cells	I-Cell
.	O

Survivin	O
is	O
a	O
novel	O
member	O
of	O
the	O
inhibitor	O
of	O
apoptosis	O
protein	O
(	O
IAP	O
)	O
family	O
.	O

Here	O
we	O
report	O
that	O
the	O
chemotherapeutic	O
drug	O
doxorubicin	O
,	O
a	O
DNA	O
-	O
damaging	O
agent	O
,	O
activates	O
a	O
p53	O
-	O
survivin	O
signaling	O
pathway	O
inducing	O
cell	B-Cell
cycle	O
arrest	O
and	O
apoptosis	O
in	O
childhood	O
acute	B-Cancer
lymphoblastic	I-Cancer
leukemia	I-Cancer
(	O
ALL	B-Cancer
)	O
.	O

Treatment	O
of	O
wild	B-Cell
-	I-Cell
type	I-Cell
(	I-Cell
wt	I-Cell
)	I-Cell
p53	I-Cell
ALL	I-Cell
cells	I-Cell
(	O
EU	B-Cell
-	I-Cell
3	I-Cell
cell	I-Cell
line	I-Cell
)	O
with	O
doxorubicin	O
caused	O
accumulation	O
of	O
p53	O
,	O
resulting	O
in	O
dramatic	O
down	O
-	O
regulation	O
of	O
survivin	O
,	O
depletion	O
of	O
cells	B-Cell
in	O
G	O
(	O
2	O
)	O
/	O
M	O
,	O
and	O
apoptosis	O
(	O
increased	O
sub	O
-	O
G	O
(	O
1	O
)	O
compartment	O
)	O
.	O

In	O
contrast	O
,	O
doxorubicin	O
treatment	O
of	O
mutant	B-Cell
(	I-Cell
mut	I-Cell
)	I-Cell
p53	I-Cell
cells	I-Cell
(	O
EU	B-Cell
-	I-Cell
6	I-Cell
/	I-Cell
ALL	I-Cell
line	I-Cell
)	O
up	O
-	O
regulated	O
survivin	O
and	O
induced	O
G	O
(	O
2	O
)	O
/	O
M	O
arrest	O
without	O
inducing	O
apoptosis	O
.	O

However	O
,	O
treating	O
EU	B-Cell
-	I-Cell
6	I-Cell
with	O
anti	O
-	O
survivin	O
antisense	O
resensitized	O
these	O
cells	B-Cell
to	O
doxorubicin	O
,	O
resulting	O
in	O
apoptosis	O
.	O

With	O
a	O
p53	B-Cell
-	I-Cell
null	I-Cell
cell	I-Cell
line	I-Cell
(	O
EU	B-Cell
-	I-Cell
4	I-Cell
)	I-Cell
,	O
although	O
doxorubicin	O
treatment	O
arrested	O
cells	B-Cell
in	O
G	O
(	O
2	O
)	O
/	O
M	O
,	O
survivin	O
expression	O
was	O
unchanged	O
,	O
and	O
cells	B-Cell
underwent	O
only	O
limited	O
apoptosis	O
.	O

However	O
,	O
re	O
-	O
expression	O
of	O
wt	O
-	O
p53	O
in	O
EU	B-Cell
-	I-Cell
4	I-Cell
cells	I-Cell
could	O
restore	O
the	O
doxorubicin	O
-	O
p53	O
-	O
survivin	O
pathway	O
,	O
resulting	O
in	O
significantly	O
decreased	O
survivin	O
expression	O
and	O
increased	O
apoptosis	O
in	O
these	O
cells	B-Cell
after	O
doxorubicin	O
treatment	O
.	O

Following	O
cotransfection	O
of	O
p53	B-Cell
-	I-Cell
null	I-Cell
EU	I-Cell
-	I-Cell
4	I-Cell
cells	I-Cell
with	O
survivin	O
promoter	O
-	O
luciferase	O
constructs	O
and	O
either	O
wt	O
-	O
p53	O
or	O
different	O
mut	O
-	O
p53	O
expression	O
vectors	O
,	O
wt	O
-	O
p53	O
inhibited	O
survivin	O
promoter	O
activity	O
;	O
p53	O
-	O
mediated	O
inhibition	O
could	O
be	O
abrogated	O
by	O
overexpression	O
of	O
murine	O
double	O
minute2	O
(	O
MDM2	O
)	O
protein	O
.	O

Together	O
,	O
these	O
studies	O
define	O
a	O
novel	O
p53	O
-	O
survivin	O
signaling	O
pathway	O
activated	O
by	O
DNA	O
damage	O
that	O
results	O
in	O
down	O
-	O
regulation	O
of	O
survivin	O
,	O
cell	B-Cell
cycle	O
arrest	O
,	O
and	O
apoptosis	O
.	O

Furthermore	O
,	O
our	O
data	O
indicate	O
that	O
loss	O
of	O
wt	O
-	O
p53	O
function	O
in	O
tumor	B-Cell
cells	I-Cell
may	O
contribute	O
to	O
up	O
-	O
regulation	O
of	O
survivin	O
and	O
resistance	O
to	O
DNA	O
-	O
damaging	O
agents	O
.	O

